Search
for
Sort by
Research 31–60 of 1000+
- Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial
- New agents for cancer chemoprevention
- Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- A Botanical Compound for the Treatment of Alopecia Areata and Chemotherapy-Induced Alopecia
- Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document
- Industry updates from the field of stem cell research and regenerative medicine in June 2019
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
- 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Faculty Opinions recommendation of Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial.
- Faculty Opinions recommendation of Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial.
- An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- PC-SPES Studies Promising, But Manufacturer Shuts Down
- The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
- Alopecia - the search for novel agents continues
- Hair characteristics and androgenetic alopecia in Koreans
- Comparison of a New 5% Minoxidil Foam and Rogaine® in the Treatment of Androgenetic Alopecia in Chinese Men: A Randomized, Double-Blind, Phase III, Equivalence Trial
- Therapeutic applications and pharmacoeconomics of microneedle technology
- The role of androgens in hormone replacement therapy
- Provenge is Talk of GU Malignancies Congress
- Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial
- Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
- Prostate cancer update: 2007
- Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia
- A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial